Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Kinoshita, Ryo ; Miyamoto, Sho ; Sakuraba, Shoko ; Sugihara, Jun ; Suzuki, Motoi ; Suzuki, Tadaki ; Yoneoka, Daisuke
• Description:
  We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).
• Subjects:
  Adolescent Adult Aged Aged, 80 And Over Antibodies, Viral Child Child, Preschool COVID-19 COVID-19 Vaccines Female Humans Infant Infant, Newborn Male Middle Aged SARS-CoV-2 Seroepidemiologic Studies Spike Glycoprotein, Coronavirus Young Adult

  More +
• Keywords:
  Children Elderly Infant Japan Maternal Immunity Respiratory Infections Seroepidemiology Seroprevalence Surveillance Vaccine-preventable Diseases Viruses Zoonoses

  More +
• Source:
  Emerg Infect Dis. 2024; 30(6):1267-1270
• Pubmed ID:
  38782366
• Pubmed Central ID:
  PMC11138984
• Document Type:
  Journal Article
• Genre:
  Dispatch
• Place as Subject:
  Japan
• Volume:
  30
• Issue:
  6
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:aea69710d4b5427f7ed7f9680db697c8ff276659f65b83241f22a43c4b426376
• Download URL:
  https://stacks.cdc.gov/view/cdc/156981/cdc_156981_DS1.pdf
• File Type:
  [PDF - 622.09 KB ]